

Disclaimer

Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our own expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited, to the following: general industry conditions and competition; risks associated with managing growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, and the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including factors such as general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; technological advances of our competitors and related legal disputes; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitor products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to "Risk Factors" section of reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). We undertake no obligation, and do not intend, to update these forward-looking statements as a result of new information or future events or developments unless and to the extent required by law.

We help advance
science and improve outcomes



Our Mission


**Enabling access to
valuable insights from
molecular research
to clinical healthcare**

Our Vision

**Making improvements
in life possible**



Helping customers to make advances in science and patient care



QIAGEN at a glance



A global company with scale

\$2.1 billion
(2022 sales)

QGEN
LISTED
NYSE
DAX
TecDAX




~45%
Americas


~35%
EMEA

~20%
Asia-Pacific / Japan

Highly recurring revenues



~88%
Consumables
and related
revenues



~12%
Instruments

Balanced customer markets

~50%
Molecular
Diagnostics

~50%
Life
Sciences



~6,200
employees known as QIAGENers

>500,000
customers worldwide

There is an unprecedented need for molecular research and testing to tackle the health challenges of our time



Our knowledge about the building blocks of life – DNA, RNA and proteins - is growing

The challenge is to make the most of this information




Tuberculosis is still one of the world's most significant infectious killers

In 2020, it killed 1.5 million people



Cancer remains a leading cause of death worldwide despite progress

It accounted for nearly 10 million deaths in 2020



Infectious diseases have been – and will remain – a truly global health risk

Six major pandemics over the past 20 years

Researchers rely on QIAGEN to advance scientific discovery

“

Targeting metabolism is an important way of sensitizing tumors and making them more responsive to chemotherapy... and it's not restricted to one particular type of cancer.

”

Asha Palat,
Doctoral Student at the university
of Houston, Texas



Physicians rely on QIAGEN to improve clinical outcomes

“

**As long as we don't have an
answer about the
respiratory virus status, we
can't admit a patient for
hospitalization.**

”

**Dr. Benoit Visseaux,
Bichat-Claude Bernard Hospital,
Paris**








We help over
500,000 customers
unlock molecular
insights that address
healthcare challenges.

That's how we help
make improvements
in life possible.



We are
known for the
highest quality
products

Our products are found in laboratories worldwide - from young scientists to Nobel laureates



Our Sample technologies are the foundation of QIAGEN



A portfolio that has grown to address the complete spectrum of processing biological samples

Selected biological samples

- ✓ Tissue
- ✓ Cells
- ✓ Blood
- ✓ Serum
- ✓ Plasma
- ✓ Urine
- ✓ Stool
- ✓ Saliva
- ✓ Other body fluids
- ✓ Bone
- ✓ Plants
- ✓ Soil



Applications

Input demands

Low / high-volume
Low-quantity
Tubes / plates

Processing

Manual



Target analytes

Genomic DNA
Plasmid DNA
cfDNA

Input demands

Low-quantity
High-quantity
Tubes / plates

Automated
Low-to
High-throughput



mRNA, rRNA,
miRNA
Proteins
Circ. Tumor cells

- ✓ Cloning
- ✓ DNA amplification
- ✓ Arrays
- ✓ Gene editing
- ✓ Epigenetic
- ✓ Cellular analytics
- ✓ qPCR / dPCR
- ✓ Sequencing / NGS
- ✓ Liquid biopsy
- ✓ Microbiome
- ✓ Gene silencing
- ✓ Proteomics

>200,000
publications
referencing QIAGEN
sample prep

QIAGEN provides solutions to uncover molecular insights – faster, better and more efficiently – from Sample to Insight



Biological sample



Sample to Insight solutions

- Sample Technologies
- Assay Technologies
- Automation Systems
- Bioinformatics




Valuable molecular insights

- Advancing knowledge about the building blocks of life – DNA, RNA and proteins
- Faster and better drug R&D
- Better disease diagnosis
- Ensuring public safety
- Better outcomes with precision medicine



What does Sample to Insight look like in the Life Sciences?



Wastewater samples are collected and brought to a lab, where RNA and DNA are extracted with QIAGEN kits and instruments



QIAGEN's QIAcuity digital PCR system is used to analyze target sequences



QIAGEN bioinformatics are used to analyze the data to monitor for new infectious disease outbreaks

70% of all U.S. states are using QIAcuity for ultra-sensitive wastewater detection of SARS-CoV-2 infections

What does Sample to Insight look like in Molecular Diagnostics?



A patient blood sample is collected using QIAGEN's proprietary blood collection tubes



QIAGEN's QuantiFERON-TB Gold Plus assay is used to analyze for latent infections with *M. tuberculosis* bacteria



Test results are delivered with one visit and in less than 24 hours

More than 70 million QuantiFERON TB tests have been completed in the global fight against TB



~\$5 billion
addressable market

QIAGEN value

2022 sales
of ~\$1 billion

Recognized innovator
supporting scientific
breakthroughs

Able to translate
innovations into
commercial products



Selected QIAGEN products

Sample technologies

- ~300 different kit types
- Liquid biopsy, tissue, blood, cells, plants, microbiome, other

Assay technologies

- Real-time PCR
- Digital PCR
- Next-generation sequencing

Instruments

- QIASymphony
- QIAcube Connect
- QIAcuity digital PCR
- RotorGene Q

Bioinformatics

- Ingenuity Pathway Analysis (IPA)
- CLC Genomics Workbench
 - Microbial Genomics
 - Metagenomics
 - Single Cell Genomics



~\$6 billion
addressable market

QIAGEN value

2022 sales
of ~\$1.2 billion

Focused on high-growth,
high-demand
opportunities

Strong automation
portfolio with multi-year
assay menu expansion
underway



Selected QIAGEN products

Sample technologies

- Tissue
- Blood
- Liquid biopsy
- Swabs, other

Assay technologies

- Indication areas
- Oncology
 - Immune modulation
 - Infectious diseases Technologies:
QFT, PCR, NGS

Instruments

- QIAstat-Dx
- NeuMoDx
- QIASymphony RGQ

Bioinformatics

- QIAGEN Clinical Insight (QCI)
- Hereditary diseases
 - Translational
 - Oncology

Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth



Pillars of Growth

Expanding on solid leadership

Sample technologies
Comprehensive portfolio

QuantiFERON
Leading immune response monitoring (incl. TB)

Early commercialization phases with strong growth potential

QIAstat-Dx
Syndromic testing with unrivaled ease of use

NeuMoDx
Differentiated microfluidic integrated PCR testing

QIAcuity
Novel microplate digital PCR

Sample technologies

Diagnostic solutions

PCR / Nucleic acid amplification

NGS / Genomics

~\$845 m

~\$690 m

~\$400 m

~\$235 m

2022 sales

Core portfolios



Microbiome



Liquid Biopsy



HID / Forensics



Immune response



Infectious diseases



Oncology / Precision Medicine



OEM Reagents



Universal NGS solutions



QIAGEN Digital Insights

And we are ready to serve public health needs across the globe

Determined to leave no country behind with a portfolio of dedicated tests and strategic partnerships

- ✓ TB testing for low-resource high-burden regions
- ✓ Testing for high-risk human papillomavirus (HPV) using the *careHPV* test
- ✓ Sample technologies supporting detection of many infectious diseases

Committed to building a sustainable business

We have set ambitious goals to contribute to a more sustainable future – never compromising on our high quality standards



By 2050:
Carbon neutral
 SBTi approved: 2030 interim goal: 42% reduction in Scope 1 and 2, 25% reduction in Scope 3

7% reduction
 in plastic transport packaging in 2023 over 2022 (16% in 2021 over 2020)



Goal: 36%
 women in leadership in 2023

2022 level: 35%

Goal: Maintain our ratings with Bloomberg Gender Equality Index and the Human Rights Campaign



100%
 Strategic suppliers committed to sustainable improvement goals by 2023

100%
 Compliance training for all new employees

Environment

Practice sustainability and protect global ecosystems

Social

Foster diversity, inclusion and access to healthcare

Governance

Ensure responsible corporate practices and compliance




Corporate Responsibility
Prime
 RATED BY **ISS ESG**

D- D D+ C- C C+ B- B B+ A- A A+



MSCI
 ESG RATINGS **A**

CCC B BB BBB **A** AA AAA



SUSTAINALYTICS

ESG Risk Rating **15.4** **Low Risk**

Ranking: Industry Group (1st = lowest risk) Pharmaceuticals

Universe: Global Universe



CDP **B-**




BEST
 PLACES TO WORK
 2022 for LGBTQ+ Equality
 100% CORPORATE EQUALITY INDEX



Bloomberg
 Gender Equality Index
 2022





>6,200
passionate QIAGENers
around the world are
employed by QIAGEN

People from all functions
working together to
achieve our vision:
Making improvements
in life possible



We have a culture of empowerment driven by achieving targets

> Decentralized decision-making

- Giving teams at all levels greater influence
- Bringing decisions closer to customers

> Ambitious but realistic targets

- Appropriately balance opportunity and risk
- Training teams on PRe-mortem analysis

> A culture of “doers”

- Foster a stronger culture of ownership
- Increase diversity in global workforce



Our strong global presence serves both developed and emerging markets



Our global and regional headquarters:

Germantown
Maryland
Americas HQ

Venlo
Netherlands
Global HQ

Hilden
Germany
EMEA HQ

Direct sales in
>30
countries

Shanghai
China HQ

Singapore
Asia-Pacific HQ

Shipping product to
>170
countries

QIAGEN is well positioned to support our customers with their rapidly evolving scientific and testing needs.

